open access

Vol 6, No 3 (2005): Practical Diabetology
Original articles (submitted)
Published online: 2005-05-16
Get Citation

LADA: pathophysiological and clinical aspects

Joanna Bobrek, Maciej T. Małecki
Diabetologia Praktyczna 2005;6(3):121-125.

open access

Vol 6, No 3 (2005): Practical Diabetology
Original articles (submitted)
Published online: 2005-05-16

Abstract

LADA is a specific form of type 1 diabetes that develops in adulthood and that is characterized by slow development of clinical symptoms. The presence of chronic immune-mediated mechanism leads to the destruction of the insulin-secreting beta-cells of the islets of Langerhans. Typical features of LADA are age at diagnosis usually over 30 years, circulating type 1 diabetes related antibodies, low C-peptide level, lack of obesity, initially good response to diet and oral medications and fast progression to clinical insulin dependency. LADA patients are often diagnosed initially with type 2 diabetes. It is very important to make a right diagnosis because early intervention with insulin may protect beta-cells, maintain their residual function over longer period of time and result in better metabolic control. The diagnosis of autoimmune diabetes is based on the presence of type 1 diabetes related antibodies, particularly glutamic acid decarboxylase antibodies (GADA). There were several studies performed on genetic background of LADA. In general the role of HLA in LADA, similarly to typical type 1 diabetes, has been confirmed. The role of other genes such as for example insulin, cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and protein tyrosine phosphatase type 22 (PTPN22) has not been defined.

Abstract

LADA is a specific form of type 1 diabetes that develops in adulthood and that is characterized by slow development of clinical symptoms. The presence of chronic immune-mediated mechanism leads to the destruction of the insulin-secreting beta-cells of the islets of Langerhans. Typical features of LADA are age at diagnosis usually over 30 years, circulating type 1 diabetes related antibodies, low C-peptide level, lack of obesity, initially good response to diet and oral medications and fast progression to clinical insulin dependency. LADA patients are often diagnosed initially with type 2 diabetes. It is very important to make a right diagnosis because early intervention with insulin may protect beta-cells, maintain their residual function over longer period of time and result in better metabolic control. The diagnosis of autoimmune diabetes is based on the presence of type 1 diabetes related antibodies, particularly glutamic acid decarboxylase antibodies (GADA). There were several studies performed on genetic background of LADA. In general the role of HLA in LADA, similarly to typical type 1 diabetes, has been confirmed. The role of other genes such as for example insulin, cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and protein tyrosine phosphatase type 22 (PTPN22) has not been defined.
Get Citation

Keywords

LADA form of diabetes; autoantibodies; genetics

About this article
Title

LADA: pathophysiological and clinical aspects

Journal

Clinical Diabetology

Issue

Vol 6, No 3 (2005): Practical Diabetology

Pages

121-125

Published online

2005-05-16

Bibliographic record

Diabetologia Praktyczna 2005;6(3):121-125.

Keywords

LADA form of diabetes
autoantibodies
genetics

Authors

Joanna Bobrek
Maciej T. Małecki

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl